Printer Friendly

ORTHOMET RECEIVES FDA APPROVAL TO MARKET ION IMPLANTED FEMORAL HEADS FOR TOTAL HIP REPLACEMENT

 MINNEAPOLIS, Feb. 25 /PRNewswire/ -- Orthomet, Inc. (NASDAQ: OMET) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) under Section 510(k) of the Food, Drug and Cosmetic Act to market Ion Implanted Femoral Heads for its hip product lines. This approval is applicable to femoral heads manufactured out of chrome-cobalt alloys.
 This new product continues to expand Orthomet offerings into segments of the orthopedic reconstructive hip market that the company did not address previously.
 Orthomet, Inc. designs, manufactures and markets selected orthopedic reconstructive implant products and related surgical instrumentation.
 -0- 2/25/93
 /CONTACT: James C. Hawley, executive vice president of Orthomet, 612-944-6112/
 (OMET)


CO: Orthomet, Inc. ST: Minnesota IN: MTC SU: PDT

AL -- MN004 -- 0308 02/25/93 10:33 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1993
Words:129
Previous Article:WINTHROP RESOURCES REPORTS RECORD EARNINGS FOR YEAR, FOURTH QUARTER
Next Article:WANG RELEASES COBOL RESOURCE DATA PROCESSING ENVIRONMENT FOR AIX
Topics:


Related Articles
ORTHOMET, INC. RECEIVES FDA APPROVAL FOR EXTENSION TO KNEE PRODUCT LINE; BEGINS TRIAL DISTRIBUTION IN U.S. OF 3M SHOULDER PRODUCT
ORTHOMET NAMES HAWLEY EXECUTIVE VICE PRESIDENT; ANNOUNCES FDA HAS APPROVED IMPORTANT KNEE IMPLANT PRODUCT FOR MARKETING
ORTHOMET RECEIVES FDA APPROVAL TO MARKET NEW HIP PRODUCTS
FDA GRANTS ORTHOMET APPROVAL TO MARKET IMPORTANT ADDITIONS TO ITS KNEE PRODUCT LINE
Stryker(R) Receives FDA Clearance for LFIT(TM) Anatomic Femoral Heads with X3(R) Liners.
Corin's hip resurfacing system approved by FDA.
Is the large-joint business booming - or boomers? The possibility of an explosion of potential patients bodes well for orthopedic manufacturers.
Panel backs approval of hip resurfacing system.
Demand for implants still going strong: non-fusion technologies, ceramics, orthobiologics expected to drive growth.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters